Optimist Retirement Group LLC Decreases Position in Organon & Co. (NYSE:OGN)

Optimist Retirement Group LLC reduced its position in Organon & Co. (NYSE:OGN - Free Report) by 61.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,165 shares of the company's stock after selling 63,000 shares during the quarter. Optimist Retirement Group LLC's holdings in Organon & Co. were worth $599,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of OGN. Pacer Advisors Inc. boosted its stake in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after purchasing an additional 11,140,388 shares during the period. Geode Capital Management LLC boosted its position in Organon & Co. by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company's stock valued at $81,288,000 after buying an additional 82,220 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Organon & Co. by 35.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company's stock worth $63,570,000 after acquiring an additional 875,128 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its position in shares of Organon & Co. by 6.4% during the third quarter. Thompson Siegel & Walmsley LLC now owns 2,262,379 shares of the company's stock worth $43,279,000 after acquiring an additional 136,457 shares during the period. Finally, Private Management Group Inc. raised its stake in shares of Organon & Co. by 11.9% in the fourth quarter. Private Management Group Inc. now owns 2,119,288 shares of the company's stock valued at $31,620,000 after acquiring an additional 225,420 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, TD Cowen raised Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $21.33.

Organon & Co. Stock Down 1.7 %

Organon & Co. stock traded down $0.26 during trading on Friday, reaching $14.63. The stock had a trading volume of 2,562,701 shares, compared to its average volume of 2,305,809. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The stock has a market cap of $3.77 billion, a PE ratio of 2.90, a P/E/G ratio of 0.83 and a beta of 0.76. The business has a 50 day moving average price of $15.37 and a 200 day moving average price of $17.69.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.